LifeSciences and BioTechnology
colorectal cancer, gut microbiota, personalized medicine
Current development stage
For Pharmaceutical development: TRL4 - POC & Safety of candidate drug formulation is demonstrated in defined animal model
Identifying, preventing, and treating patients at high risk for developing colorectal cancer.
The present invention is based on the surprising finding that gut microbiota, and in particular polyphenol producing microbiota, promotes colorectal cancer, and has a clear pro-tumorigenic effect on patients with a specific genetic background.
Our innovation suggests a method to prevent and treat cancer by exposing the patient to gradually reduced amounts of the discovered specific polyphenol.
Personalized monitoring of microbiota and the associated metabolites content for colorectal cancer patients or people bearing high risk for the disease. The technology will also be used to prevent the development of colorectal cancer in high risk patients as well as treat patients already afflicted by colorectal cancer through dietary measures, antibiotic treatment, or administration of small molecules that reduce the amount of the specific polyphenol .
VP Business Development Healthcare
HUJI, School of Medicine - IMRIC
Immunology and Cancer Research